14-118 C.M.R. ch. 19, § 3 - Definitions

A. Community-based Agency: Any agency, coalition, association, or organization, that has registered as a corporation or other business organization with the Office of the Secretary of State and that is in good standing with that office, or any municipality, local or county government entity. The Community-based Agency must in some capacity provide services to populations at high risk for drug overdose.

B. Healthcare Professional: Any individual licensed under Title 32 of the Maine Revised Statutes who is authorized to prescribe Naloxone Hydrochloride within the scope of professional competency.

C. Medical Supplies Necessary to Administer Naloxone Hydrochloride: Items intended to facilitate the administration of Naloxone Hydrochloride, including but not limited to syringes, atomizers, rescue breathing masks, rubber gloves, alcohol pads, and educational inserts.

D. Naloxone Hydrochloride: An opioid antagonist approved by the United States Food and Drug Administration that when administered can temporarily stop or reverse the effects of an Opioid-related Drug Overdose.

E. Opioid-related Drug Overdose: A condition including, but not limited to, extreme physical illness, decreased level of consciousness, respiratory depression, coma or death resulting from the consumption or use of an opioid, or another substance with which an opioid was combined, or a condition that a reasonable person would believe to be an Opioid-related Drug Overdose that requires medical assistance.

F. Overdose Prevention Program: A program established by a Community-based Agency that has the goal of increasing awareness of opioid use and overdose prevention.

G. Standing Order: A written order for a medication authorizing the dispensing of the medication when specified predetermined conditions have been met. Consistent with 22 M.R.S. §2353(2), a Standing Order for Naloxone Hydrochloride allows a Healthcare Professional to issue an order without the Healthcare Professional necessarily interacting directly with the ultimate recipient of the medication.

Notes

14-118 C.M.R. ch. 19, § 3